Abstract. The use of highly specific and highly sensitive immunofluorescent probes is a promising approach for biomedical imaging in living tissue. We focus on immunofluorescence with quantum dot bioconjugates for hepatoma detection in vivo. We synthesized specific immunofluorescent probes by linking quantum dots to AFP ͑alpha-fetoprotein͒ antibody for specific binding AFP-an important marker for hepatocellular carcinoma cell lines. In in vivo studies, the characteristic quantum dot ͑QD͒ fluorescent property is exhibited by the QDs-Anti-AFP probes in tumor and they demonstrate active tumor targeting and spectroscopic hepatoma imaging with an integrated fluorescence imaging system. We investigate the inhomogeneous distribution of the QDs-Anti-AFP probes in tumor by using a site-by-site measurement method to test their ability for distribution studies of cancer cells. These results demonstrate the practicality of QD bioconjugates as attractive fluorescent probes for biomedical detection.
Introduction
Quantum dots ͑QDs͒ are a promising alternative to organic immunofluorescent probes for cancer detection. [1] [2] [3] [4] [5] [6] [7] [8] [9] Several characteristics distinguish QDs from commonly used fluorophores, such as broad absorption spectra, size-and composition-tunable, narrow fluorescence emission, and very high levels of brightness and photostability. [10] [11] [12] [13] [14] [15] [16] For in vivo detection, clinical values of QDs as immunofluorescent probes require them to have high sensitivity and high specificity for cancer cells. 2 In one previous study, QDs were linked to immunoglobulin G ͑IgG͒ and streptavidin to label the breast cancer marker Her2 on the surface of fixed and live cancer cells, which showed that QD probes can be very effective in cellular imaging and offer substantial advan-tages over organic dyes. 17 In another study, QDs were first used as stable fluorescent tracers for nonspecific uptake studies and lymph node mapping in living animals. 1 In an important improvement, PEG-coated QDs were functionalized with antibodies to prostate-specific membrane antigen and were intravenously injected in mice for tumor targeting and imaging. 2 Most recently, self-illuminating quantum dot conjugates as new probes were first used in in vivo imaging. 6 However, there is no reported study of using immunofluorescent QD bioconjugates for in vivo hepatic cancer detection.
In this study, we aim to examine the sensitivity and specificity of the QD probes to hepatoma in mice and achieve attractive biomedical detection. We synthesized specific immunofluorescent probes by linking QDs to alpha-fetoprotein ͑AFP͒ antibody for specific recognization of AFP-an important marker for hepatocarcinoma cell line HCCLM6 ͑Ref. 18͒. In vivo, we achieved active tumor targeting and sensitive spectroscopic hepatoma imaging with an integrated fluorescence imaging system. We also investigated the inhomogeneous distribution of the QD probes in tumor by using a siteby-site measurement method to test their ability for distribution studies of cancer cells in tumor. These results demonstrate the potential of QD probes as attractive immunofluorescent probes for cancer detection.
Materials and Methods

Materials
Core-shell QDs ͑ZnS-capped CdSe, Ref. 15͒ were synthesized by College of Chemistry & Molecular Sciences, Wuhan University. Human hepatocellular carcinoma cell lines 18 ͑HCCLM6͒ were provided by Liver Cancer Institute of Fudan University. EDC ͑1-͑3-Dimethyl-aminopropyl͒-3-ethylcarbodiimide hydrochloride, Ͼ98%͒ and NHS ͑N-hydroxysuccinimide, Ͼ98%͒ were purchased from AcrosOrganics. Mouse anti-human monoclonal AFP antibody and RPMI-1640 culture medium were purchased from Sigma.
QDs Bioconjugation and Animal Preparations
We used a 1.5-ml solution of high-quality oil-soluble coreshell QD590 to synthesize water-soluble QDs according to a developed procedure. 15 These activated dots modified with thioglycolic acid were dissolved in phosphate-buffered saline ͑PBS͒ ͑0.08 mol/ l, pH 7.4͒ containing 50 mmol EDC and 5 mmol NHS. Then, the QDs were reacted with 20 l mouse anti-human monoclonal AFP antibodies at room temperature in a shaking incubator for 2 to 4 h. The final QD bioconjugates were purified by centrifugation at 6000 g for 10 min, and the suspension was dialyzed for 8 to 12 h. The QDs-Anti-AFP thus afforded were stored in refrigerator at 4°C.
Using protocols approved by the Institutional Animal Care and Use Committee of Wuhan University, ϳ10 6 prepared HC-CLM6 cells were injected into a 6-to 8-week-old nude mouse subcutaneously. Tumor growth was monitored daily until it reached the acceptable size ͑0.5 to 1 cm in diameter͒. Then, the synthesized QDs-Anti-AFP probes were injected into the tail vein at 0.4 nmol for active targeting ͑four times͒. The time interval between each injection was about 24 h. The mice were placed under anesthesia by injection of 3% Nembutal at a dosage of 45 mg/ kg for in vivo studies.
Some other mice bearing tumors of similar sizes ͑0.5 to 1 cm in diameter͒ were prepared under the same protocols for histological examination. The same dose ͑0.4 nmol͒ of QDs and QDs-Anti-AFP were injected into different mice for passive and active targeting. After a 24-h probe circulation, the mice were killed and tumors and major organs were removed and frozen. Tissue collections were cryosectioned into sections ͑10 m thick͒, fixed with acetone at 0°C, and examined with a confocal fluorescence microscope ͑Leica TCS-SP2-AOBS-MP, D-68165, Mannheim, Germany͒.
Fluorescence Detection and Imaging
The fluorescence imaging system is shown in Fig. 1͑A͒ . The pulsed laser was provided by a Ti:sapphire laser ͑Mira 900, Coherent͒. Samples were excited at the wavelength of 400 nm using an optical frequency-doubling system. The beam was focused on samples with a lens. The fluorescence over the entire emission range was collected by a liquidnitrogen-cooled CCD-array spectrometer ͑ACTON, Spectrapro 2500I͒ along with imaging acquisition and analysis software. The following samples were prepared for fluorescence detection: ͑1͒ QDs and QDs-Anti-AFP and ͑2͒ QDs-tagged tumor tissue and normal tissue in a nude mouse ͓Fig. 1͑A͔͒.
Site-by-Site Measurement for Distribution Analysis
We selected 2500 sampling sites covering a square area from the periphery to the central area in the tumor of a nude mouse, and each side of the square consists of 50 equidistant sites. An X-Y axis translation stage was designed to shift the QDlabeled mouse automatically ͓Fig. 1͑A͔͒. When the fluorescence emission of one site was collected, the stage was shifted 0.1 mm along one axis to focus the laser on the next site. After 2500 continuous collections, all the recorded emission peak intensities were processed by software to form a contour map ͑Fig. 2͒ to indicate the fluorescence intensity distribution of the detected area.
Results and Discussion
Spectral Characteristic
The QDs and the QDs-Anti-AFP probes have the same narrow and symmetric emission spectrums ͑Fig. 3͒. The corresponding emission peaks are at 590 nm and half-maximum values are only 20 nm. The QDs-Anti-AFP probes used in this study exhibit the same excellent spectral property as the original QDs. Note that the exposure times of QDs ͑8 ms͒ and QDs-Anti-AFP ͑10 ms͒ were different for spectral matching.
In vivo Cancer Detection
To investigate the specific binding of QDs-Anti-AFP to hepatoma in vivo, we used QDs-Anti-AFP to target AFP for active targeting. 2, 19 AFP is the main component of mammalian fetal serum, which is synthesized by visceral endoderm of yolk sac and by fetal liver cells. The alteration of AFP blood level is an important marker for hepatocellular carcinoma, so that the accumulation and retention of AFP at the site of tumor is the basis of immunofluorescence detection and targeted therapy for hepatic cancer. 20 The fluorescence spectral feature of QDs-tagged tumor tissue almost fits that of the original QDs, and the quantitative spectral comparison ͓Figs. 1͑D͒ and 1͑E͔͒ demonstrate that QD emission in tumor can be clearly distinguished from tissue autofluorescence. The spectroscopic imaging of the tumor tissue ͓Fig. 1͑B͔͒ exhibits strong QD fluorescence at 590 nm and relatively weak tissue autofluorescence. In contrast, the spectroscopic imaging of the normal tissue ͓Fig. 1͑C͔͒ shows only autofluorescence background. These results indicate that the QDs-Anti-AFP probes have specific and attractive binding to hepatoma in vivo. Note that the QD probes in nude mice were excited with femtosecond laser pulses in our study, so that the sampling sites for spectroscopic imaging are only a part of the tumor, not the whole mouse. The use of a macroillumination system 1,2,21 should be an adapted alternative for whole animal studies.
In addition, the control study results with the same dose of nontargeted QDs and QDs-Anti-AFP are shown in Fig. 4 ͑0.4 nmol injected plus a 24-h latent period of probe circulation͒. Little QD accumulation was found in tumors due to passive tumor targeting, while QDs-Anti-AFP were detected by their clear characteristic fluorescence. Note that nonspecific liver and spleen uptake was apparent in organ uptake studies ͑image not shown͒, which is similar to that of QD-PSMA biconjucgates. 
Distribution Analysis
It has been shown that the QD probes can be targeted to tumor cells through both passive and active mechanisms ͑effected by cell membrane alignment along adhesive surfaces 19 ͒, but passive targeting ͑due to permeation and retention of QDs at tumor sites 1, 2, 22, 23 ͒ is much less efficient than active targeting ͑Fig. 4͒ ͑due to QD-antibody binding to tumor-specific ͒. Thus, the necrotic cancer cells lacking specific antigen are almost deprived of the ability to bind to the QD probes, and the distribution of QD probes in tumor is mainly attributed to the density of cancer cells with specific antigens for active targeting. Consequently, a fluorescence intensity contour map ͑Fig. 2͒ was plotted by using the site-by-site measurement method already discussed for distribution analysis. Different colors in the map show the inhomogeneous distribution of cancer cells ͑with probes͒ in the detected area of the tumor. Since cold colors represent a lower fluorescence intensity in the area, and lower intensity corresponds to fewer QD probes among the sampling sites, it is clear that the cancer cells per field in the central area were less than the periphery area of the tumor. Although some singular points ͑such as the orange and red areas in the lower right-hand corner and the upper middle region of the map͒ do not match the whole tendency of color changes because of the complexity of tumor's structure, the fluorescence intensity contour map exhibit that the number of cancer cells ͑with probes͒ per field is lower inside than those outside. Note that the result does not provide an absolute intensity comparison among these sites because several factors ͑such as complexity of tumor's structure and optical density of sampling sites͒ are difficult to normalize or calibrate. Instead, it is just a qualitative fluorescence intensity comparison, demonstrating the distribution of the cancer cells with QD probes in the tumor. Similarly, histological examinations have shown that the density of the vascular distribution in tumor is also inhomogeneous. It accumulates in the periphery and is scarce or absent in the central area, so that the process of nutrient competition causes more necrotic cells inside than outside in the tumor. 24 Further, the distribution result is consistent with the universal dynamics theory of tumor growth. 25 Unfortunately, the maximum shifting distance of the automatic X-Y axis translation stage in our study is only 5 mm, not enough for whole tumor studies. However, this problem could be solved with improved experimental conditions. Notwithstanding this limitation, these results demonstrate the QD probes are specific and sensitive enough for distribution analysis of a tumor in vivo.
Conclusions
Using QD bioconjugates as immunofluorescent probes for cancer detection is challenging. The indirect immunofluorescence method we adopt is based on the combination of AFP antibody and core-shell QD590. The synthesized QDs-Anti-AFP probes serve as secondary antibodies to combine with specific AFP ͑as primary antibody͒. The method we adopted is more convenient and practical than traditional streptavidinbiotin technique. 26 The optical examinations aim to archive specific and sensitive fluorescence detection with the complex QD probes. In in vivo conditions, the QDs-Anti-AFP in a tumor exhibit the characteristic QD fluorescence, and enable active tumor targeting and spectroscopic hepatoma imaging. In contrast, the same doses of nontargeted QDs were found to have little accumulation in tumors due to passive targeting following the same length of circulation. Further, by using the site-by-site measurement method, the probes show the practicality of the investigation of cancer cell distribution in vivo in a tumor. In addition, a remaining issue is the toxicity and metabolism of QD bioconjugates in vivo, which have been discussed by other groups. 2, [27] [28] [29] [30] We expect that the bright, specific, and sensitive QD-based bioconjugates will be ideal immunofluorescent probes for multiplexed cancer detection and diagnosis.
